Therapeutic | Efungumab |
Target | Heat Shock Protein 90 Homolog |
Heavy Chain | EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS |
Light Chain | DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | scFv |
Isotype | na |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2006 |
INN Year Recommended | 2007 |
Companies Involved | NeuTec Pharma |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Breast cancer, Candidiasis |
Notes |